Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Loading...
Embargo End Date
ICR Authors
Authors
Bygrave, C
Pawlyn, C
Davies, F
Craig, Z
Cairns, D
Hockaday, A
Jenner, M
Cook, G
Drayson, M
Owen, R
Gregory, W
Morgan, G
Jackson, G
Kaiser, M
Pawlyn, C
Davies, F
Craig, Z
Cairns, D
Hockaday, A
Jenner, M
Cook, G
Drayson, M
Owen, R
Gregory, W
Morgan, G
Jackson, G
Kaiser, M
Document Type
Journal Article
Date
2020-06-10
Date Accepted
2020-05-05
Abstract
Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within 12 months of autologous stem cell transplant was associated with markedly worse median progression-free survival 2 (PFS2) of 18 months and overall survival (OS) of 26 months, compared to median PFS2 of 85 months and OS of 91 months for later relapsing patients despite equal access to and use of subsequent therapies, highlighting the urgent need for improved outcome prediction and early intervention strategies for myeloma patients.
Citation
British journal of haematology, 2020
Source Title
Publisher
WILEY
ISSN
0007-1048
eISSN
1365-2141
Collections
Research Team
Myeloma Biology and Therapeutics
Myeloma Group
Myeloma Group